Characteristics of subjects
| Characteristic . | Median (range) or N (%) n = 36 . |
|---|---|
| Age, y | 68 years (47-78) |
| Female/male, n | 13/23 |
| Time from diagnosis | 7 weeks (2-107) |
| Baseline | |
| Hgb, g/dL | 9.7 (7.1-14.6) |
| Plt, × 103/mL | 65 (3-523) |
| ANC, × 103/mL) | 0.840 (0.24-13.3) |
| Epo, MIU/mL | 108 (17.6-1316.0) |
| Blast % | 11.1 (1-19) |
| IPSS, n | |
| Int-1 | 5 (14) |
| Int-2 | 20 (56) |
| High | 11 (31) |
| IPSS cytogenetics risk group (n = 19), n | |
| Good | 8 (42) |
| Intermediate | 6 (32) |
| Poor | 4 (21) |
| No growth | 1 (5) |
| WHO classification, n | |
| RA | 2 (6) |
| CMML-2 | 3 (8) |
| RAEB-1 | 10 (28) |
| RAEB-2 | 21 (58) |
| Previous therapies, n (%) | |
| Growth factors | 7 (19) |
| Immunosuppressants | 5 (14) |
| Chemotherapy | 6 (17) |
| Median cycles on-study, n (range) | 5 (1-7) |
| Characteristic . | Median (range) or N (%) n = 36 . |
|---|---|
| Age, y | 68 years (47-78) |
| Female/male, n | 13/23 |
| Time from diagnosis | 7 weeks (2-107) |
| Baseline | |
| Hgb, g/dL | 9.7 (7.1-14.6) |
| Plt, × 103/mL | 65 (3-523) |
| ANC, × 103/mL) | 0.840 (0.24-13.3) |
| Epo, MIU/mL | 108 (17.6-1316.0) |
| Blast % | 11.1 (1-19) |
| IPSS, n | |
| Int-1 | 5 (14) |
| Int-2 | 20 (56) |
| High | 11 (31) |
| IPSS cytogenetics risk group (n = 19), n | |
| Good | 8 (42) |
| Intermediate | 6 (32) |
| Poor | 4 (21) |
| No growth | 1 (5) |
| WHO classification, n | |
| RA | 2 (6) |
| CMML-2 | 3 (8) |
| RAEB-1 | 10 (28) |
| RAEB-2 | 21 (58) |
| Previous therapies, n (%) | |
| Growth factors | 7 (19) |
| Immunosuppressants | 5 (14) |
| Chemotherapy | 6 (17) |
| Median cycles on-study, n (range) | 5 (1-7) |
ANC indicates bsolute neutrophil count; CMML, chronic myelomonocytic leukemia; Epo, erythropoietin level (for all subjects); Hgb, hemoglobin; Int, intermediate; IPSS, International Prognostic Scoring System; Plt, platelet count; RA, refractory anemia; RAEB, refractory anemia with excess blasts; and WHO, World Health Organization.